NLG919

Research use only, not for human use.

NLG919 is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM in cell-free assays. Phase 1.

NLG919 is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM in cell-free assays. Phase 1.(In Vitro):IDO-IN-7 (NLG-919 analogue) is a potent IDO1 inhibitor (IC50=38 nM). The binding mode of IDO-IN-7 to IDO1 is experimentally available and shows a direct coordinative interaction to the sixth coordination site of ferric heme. IDO-IN-7 has been used as reference compound in other studies to validate high-throughput screening assay for IDO1 inhibition and develop immunostimulatory nanomicellar carrier.

IDO-IN-7 (NLG-919 analogue) is a potent IDO1 inhibitor (IC50=38 nM). The binding mode of IDO-IN-7 to IDO1 is experimentally available and shows a direct coordinative interaction to the sixth coordination site of ferric heme. IDO-IN-7 has been used as reference compound in other studies to validate high-throughput screening assay for IDO1 inhibition and develop immunostimulatory nanomicellar carrier.

——

GDC-0919

Metabolic Enzyme/Protease

IDO

IDO

Cancer

——

1402836-58-1

282.38

C18H22N2O

>98% (HPLC)

Ethanol: 56 mg/mL warmed (198.31 mM); DMSO: 15 mg/mL warmed (53.11 mM)

OC(C1CCCCC1)CC(C2=C3C=CC=C2)N4C3=CN=C4

1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol

(-20℃)

With Ice Pack

≥ 2 years